sintilimab
eli lilly
['sintilimab', 'nsclc', 'sclc']
neoscore: 2 vs. 3 cycles of neoadjuvant sintilimab plus chemotherapy in resectable nsclc (ib-iiia) primary endpoint: mpr
n=60
mpr: 26.9% (2 cycles) vs. 41.4% (3 cycles)
pcr: 19.2% vs. 24.1%
higher mpr with squmaous cell vs. adeno very intriguing data. await mature data #asco22 
Oncologist taking care of people with cancer at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM